[Comparative study of the safety and reactogenicity of different doses of brucellosis chemical vaccine in human revaccination]. / Sravnitel'noe izuchenie bezvrednosti i reaktogennosti razlichnykh dozirovok brutselleznoi khimicheskoi vaktsiny pri revaktsinatsii liudei.

The period of 11-12 months has been found to be the optimal interval, among other experimentally tested periods of time, between primary immunization and booster immunization with chemical brucellosis vaccine. The safety and low reactogenicity of different doses (1 mg, 0.75 mg and 0.5 mg) of the vaccine have been established. The occurrence and intensity of local and systemic reactions to this vaccine depend neither on the dose of the preparation, nor on previous immunization.

[Comparative study of the antigenic activity and allergic transformation of the body in human revaccination with different doses of a chemical brucellosis vaccine]. / Sravinitel'noe izuchenie antigennoi aktivnosti i allergicheskoi perestroiki organizma pri revaktsinatsii liudei raznymi dozami brutselleznoi khimicheskoi vaktsiny.

The study of different doses of chemical brucellosis vaccine (0.5 mg, 0.75 mg and 1 mg), used for the booster immunization of persons who had received primary immunization with chemical and live brucellosis vaccines, revealed that the characteristics of its antigenic potency were somewhat higher after primary immunization with the live vaccine. When used for booster immunization, the tested doses showed no differences in their antigenic potency irrespective of prior immunizations received by the immunized persons. In booster immunization chemical brucellosis vaccine was found to have poorly pronounced allergenic properties irrespective of its booster dose with the tendency towards greater sensitization to brucellosis allergen in persons primarily immunized with the live vaccine. When considering the possibility of using brucellosis chemical vaccine in medical practice, the complex evaluation of the characteristics showing its reactogenicity and antigenic potency, as well as the allergic transformation of the body induced by the injection of the vaccine, was carried out, which made it possible to recommend 1 mg of the vaccine as the optimal booster dose.

[Use of a Brucella protein-polysaccharide antigen for the allergen diagnosis of brucellosis]. / Ispol'zovanie belkovo-polisakharidnogo antigena brutsell dlia allergodiagnostiki brutselleza.

The experimental and clinical study of the allergen diagnostic properties of new Brucella protein-polysaccharide antigen in comparison with brucellin has been made in the leukocyte migration inhibition test, and its working doses have been determined. The results thus obtained suggest that Brucella protein-polysaccharide antigen has considerable diagnostic advantages over commercial brucellin, which presents vast possibilities of using this antigen for the allergen diagnosis of brucellosis in the leukocyte migration inhibition test.

[Comparative study of the safety, reactogenicity and antigenic activity of chemical and live brucellosis vaccines in a controlled epidemiological trial]. / Sravnitel'noe izuchenie bezvrednosti, reaktogennosti i antigennoi aktivnosti brutselleznoi khimicheskoi i zhivoi vaktsin v usloviiakh kontroliruemogo épidemiologicheskogo opyta.

The complex evaluation of the reactogenicity characteristics revealed that after immunization with chemical brucellosis vaccine systemic reactions observed in most of the vaccinees were mildly pronounced and local reactions, mildly and moderately pronounced, their duration not exceeding 48-72 hours. During 4 months after immunization the antigenic and immunogenic potency of chemical brucellosis vaccine was no different from that of live brucellosis vaccine; seropositive persons immunized with chemical and live brucellosis vaccines showed no statistically significant differences in the geometric mean of their antibody titers, as determined in a number of serological tests, for a year after immunization. The examination of the vaccinees 4 and 12 months after immunization revealed that the sensitizing activity of chemical brucellosis vaccine was, respectively, 12.2 and 2.5 times lower than the allergenic action of live brucellosis vaccine.

[Determination of the optimal inoculation dose of Brucella chemical vaccine]. / Opredelenie optimal'noi privivochnoi dozy brutselleznoi khimicheskoi vaktsiny.

Brucellosis chemical vaccine, when injected intramuscularly, proved to be low-reactogenic, postvaccinal reactions, both systemic and local, becoming less frequent and intense with the decrease of the dose from 2 to 0.5 mg. The highest antigenic and immunogenic activity was observed with a dose of 1 mg; out of 4 tested doses this dose produced the highest percentage of seroconversions, the highest titers of agglutinins and the longest time of their persistence in the subjects. When introduced in doses of up to 2 mg, brucellosis chemical vaccine did not induce pronounced sensitization. A high degree of correlation between the indices of seroconversion frequency in Wright's agglutination test and Huddleson's test was established after vaccination with all tested doses. This fact indicates that one of these tests can be used for the assessment of the antigenic and immunogenic activity of the vaccine at an early period after immunization (the term of observation not exceeding 3 months). On the basis of the complex comparison of the indices characterizing the reactogenicity and the antigenic and immunogenic activity of 4 tested doses of brucellosis chemical vaccine a dose of 1 mg was chosen as the optimum vaccination dose.

[Immunity status of guinea pigs infected with Brucella L forms]. / Izuchenie sostoianiia immuniteta u morskikh svinok, zarazhennykh L-formami Brucella.

B. abortus L-forms injected subcutaneously into guinea pigs adapt in the lymph nodes of the animals in the absence of reversion to normal cells. Complete and incomplete antibodies belonging to macro- and microglobulins (IgM and IgG) were synthetized. The allergic transformation of the organism is faintly pronounced. After this form of infection guinea pigs become resistant to B. melitensis infection for 6 months (the term of observation).

On the pathogenicity of nonstable Brucella L-forms and their revertants.

The pathogenicity of B. abortus 870 L-forms obtained by long-term passaging of virulent culture on media with penicillin and of revertants obtained in vitro and in vivo was studied. L-form cultures stimulated only a mild response of the reticulo-endothelial system of the animal organism, at the same time displaying a certain level of toxicity. In vitro revertants approximated to L-forms, while in vivo revertants stood closer to the initial virulent culture, as regards pathogenicity. This seems to be evidence of a potential danger of brucella L-forms for the human and animal organisms.

[Character of the immune response in guinea pigs following immunization with brucellosis protective antigen]. / Kharakter immunogo otveta u morskikh svinok pri immunizatsii brutselleznym protektivnym antigenom

In studying guinea pigs immunized with brucella protective antigen and the immunological response in them it was found that the antigen could be determined for 30 days by the method of fluorescent antibodies in the cells of the lymph nodes and the spleen following its intravenous injection. The optimal immunizing dose was 0.6 mg; in difference from a dose of 2 mg it produced an earlier and a more pronounced humoral effect. The phagocytic activity of the peritoneal macrophages of guinea pigs immunized with low doses was much more intensive than of those immunized with high doses of the antigen. Brucella protective antigen in a dose of 2 mg produced a disturbance of the carbohydrate metabolism in phagocytes, this influencing negatively their phagocytic function.

[Role of clasmatosis of the phagocytes in immunogenesis]. / O roli klazmatoza fagotsitov v immunogeneze

With the aid of cytological and cytochemical studies it was shown that clasmatosis of phagocytes (micro- and macrophages) was primarily characteristic of active phagocytising cells, and not of dying cells as considered formerly. Experiements were conducted on guinea pigs in the course of vaccinal and infectious processes in brucellosis. As noted, clasmatosis of phagocytes known in intact animals was considerably enhanced during vaccinal and infectious processes. Pieces of cytoplasm separating from phagocytes were full of acid phosphatase, brucella antigen; fragments of macrophage cytoplasm in addition contained RNA. There are reasons to suppose that with the aid of clasmocytosis of phagocytes became intensified and the antigenic information spread rapidly in the animal organism.

[Brucellosis protective antigen, its chemical and immunobiological characteristics]. / Brutselleznyi protektivnyi antigen, ego khimicheskaia i immunologicheskaia kharakteristika

The data on brucella nontoxic protective antigen without any sensitizing properties isolated from the cell wall of brucella are presented. The antigen had a marked protective effect against the experimental infection for 3-4 months after a single immunization of guinea pigs.Molecular heterogeneity of the antigen, which is mainly a protein-polysaccharide complex, is given. High- and low-molecular fractions detected by gel filtration technique differed according to the chemical and immunobiological characteristics. The high-molecular fraction of the antigen was found to be highly immunogenic and serologically active.

[Immunogenic properties of brucella protective antigen upon revaccination]. / Izuchenie immunogennykh svoistv brutselleznogo protektivnogo antigena pri revaktsinatsii

The authors generalized the materials on the experimental study of the immunological efficacy of brucella protective antigen in revaccination. Revaccination 12 months after the immunization of guinea pigs with an antigen in a dose equal to the primary immunization dose (0.6 mg) reproduced the protection from the infection with a virulent Br. melitensis culture in 78% of the animals. The antigen proved to be effective only at the remote period between the revaccination and the primary antigen vaccination (12 months). The data obtained pointed to a high protective action of the antigen in the guinea pig revaccination 9 to 12 months after their immunization with live brucella Br. abortus 19-BA vaccine.